Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q1 FY21 results · Apr–Jun 2020
Jubilant Pharmova reported revenue from operations of ₹1,892.92 crore (down 13.2% from Q1 FY20) and net profit of ₹88.01 crore (down 52.4% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,892.92 | 2,181.86 | −13.2% | 2,391.41 | −20.8% |
| Other income | 8.13 | 9.70 | −16.2% | 19.44 | −58.2% |
| Total income | 1,901.05 | 2,191.56 | −13.3% | 2,410.85 | −21.1% |
| Profit before tax | 122.10 | 269.03 | −54.6% | 355.95 | −65.7% |
| Net profit for the period | 88.01 | 184.98 | −52.4% | 260.49 | −66.2% |
| EPS, basic (₹) | 5.53 | 11.61 | −52.4% | 16.35 | −66.2% |
| Net margin (%) | 4.6 | 8.5 | 10.9 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 753.95 | 789.82 | −4.5% | 791.36 | −4.7% |
| Other income | 8.98 | 5.94 | +51.2% | 82.69 | −89.1% |
| Total income | 762.93 | 795.76 | −4.1% | 874.05 | −12.7% |
| Profit before tax | 71.08 | 47.32 | +50.2% | 110.36 | −35.6% |
| Net profit for the period | 52.04 | 32.26 | +61.3% | 111.18 | −53.2% |
| EPS, basic (₹) | 3.27 | 2.03 | +61.1% | 6.98 | −53.2% |
| Net margin (%) | 6.9 | 4.1 | 14.0 |
Consolidated
- Filed with BSE
- 04 Sep 2020, 20:00 IST
- Board meeting
- 04 Sep 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Sep 2020, 20:00 IST
- Board meeting
- 04 Sep 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE